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Patients with sickle cell disease (SCD) suffer from anemia and painful vaso-occlusive crisis (VOC) and sometimes need blood
transfusions. Delayed hemolytic transfusion reaction (DHTR) is a rare life-threatening complication observed in SCD andmimics
VOC. We describe a female SCD patient undergoing three surgical procedures during which DHTR developed following the first
two. Prior to a planned tonsillectomy, she received transfusion and three days after surgery developed severe hemolysis as well as
pain and respiratory symptoms. On suspicion of VOC, she received additional transfusions and became hemodynamically
unstable, and her hemolytic anemia worsened. Gradually, she recovered and could be discharged after two weeks; DHTR was not
suspected. Sixteen months later, an arthroplasty was performed due to avascular necrosis, and again she was transfused pre-
operatively. Similar to the initial surgery, she developed symptoms and signs of VOC after three days, but this time, DHTR was
suspected and further transfusions were withheld. Although immunosuppressive medication did not alleviate the condition, she
improved on combined treatment with darbepoietin, rituximab, and eculizumab. Six months later, a second arthroplasty was
performed uneventfully after prophylaxis with rituximab and without transfusion. DHTR should be considered in the presence of
severe, unexplained hemolysis following a recent transfusion, and additional transfusions in this setting should be given only on
vital indication.
1. Introduction
Sickle cell disease (SCD) is an inherited hemoglobinop-
athy prevalent in equatorial regions such as sub-Saharan
Africa. *is is partly because carriers (heterozygotes) of
the mutated sickle cell gene are protected against fatal
complications of severe malaria [1]. *e disease is char-
acterized by hemolytic anemia, infections, and vaso-oc-
clusive crisis (VOC) with acute as well as chronic pain,
leading to significant lifelong morbidity and increased
mortality.
In case of severe anemia, blood transfusions may be
indicated in SCD. Repeated transfusions often result in the
formation of anti-red blood cell (RBC) alloantibodies, and
alloimmunization occurs more frequently in SCD patients
than in other heavily transfused patient groups [2]. *e
prevalence of alloimmunization in SCD patients is report-
edly between 30% and 50% [2, 3]. Delayed hemolytic
transfusion reaction (DHTR) is a life-threatening compli-
cation due to alloimmunization. Generally, DHTR is rare,
but it has been typically described among SCD patients,
possibly due to mismatch between donor-RBC antigens
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(mainly Caucasian) and SCD-recipients (mainly Africans)
[4]. *ere is to date no consensus definition of DHTR, but it
is characterized by unequivocal evidence of severe hemolysis
leading to a marked drop in hemoglobin levels below pre-
fusion level, with or without detectable alloantibodies, and
often appearing within 24 hours to 3 weeks after transfusion
[5]. *e true prevalence of DHTR among SCD patients is
difficult to assess since this condition is probably often
undiagnosed, but a prevalence ranging from 4% to 8% of
transfused adult SCD patients has been reported with those
receiving acute transfusions being at highest risk compared
to those receiving chronic transfusions [6, 7].
Our knowledge about DHTR stems from case reports
and case series usually involving only one DHTR event per
patient.We here present an unusual case of repeated DHTRs
without documented alloimmunization in a SCD patient
treated at our unit on three different occasions where we
suspect DHTR as the major underlying mechanism of the
severe complications observed during the first two admis-
sions. Consequently, a different approach to the third ad-
mission led to an uneventful clinical course.
2. Case Presentation
A 28-year-old Nigerian female with homozygous SCD be-
came a regular outpatient at our department in 2013 after an
uneventful (without any blood transfusion) pregnancy and
birth in the USA. As a child, she had received several
transfusions, apparently with no complications. She had the
following blood type profile: 0; D+; C-; E-; c+; e+; K-; S-; in
addition to anti-C and anti-E antibodies. She had never used
any medication except folic acid.
2.1. Episode 1. In May 2017, she underwent an elective
tonsillectomy at our hospital (a tertiary reference center in
Norway; day 0). Except for routine pre-transfusion
screening, neither extended screening for new alloantibodies
nor a direct antiglobulin test was performed. On day −1, she
received a scheduled transfusion of two cross-matched units
of RBC with hemoglobin (Hb) increasing from a baseline
value of 7 to 9.0 g/dl. After an uncomplicated procedure, she
was transferred to a local hospital with an uneventful clinical
course until day +4 when she developed generalized skeletal
pain and fever, but no chest or respiratory symptoms. As
Figure 1 shows, her Hb declined till day +5. *ere were
concurrent signs of increased hemolysis with total bilirubin
increasing to 5.5 mg/dl and lactate dehydrogenase (LDH)
more than tripled in the same time period. On suspicion of
VOC, she was on day +4 treated with analgesics, fluids, low-
molecular-weight heparin, and antibiotics according to our
guidelines. Her condition deteriorated within the next 24
hours, and she became increasingly respiratory distressed. A
CT scan showed bilateral pulmonary infiltrates. Acute chest
syndrome was suspected, and she received partial exchange
transfusion with two cross-matched units of RBC, resulting
in a transient Hb rise. Two additional units of RBC were
administered, and the patient was transferred to the in-
tensive care unit on day +6. Hb was then 6.9 g/dl, which over
the next 6 hours fell to 5.1 g/dl. LDH peaked at 4,974U/l,
whereas haptoglobin was not detectable. Retrospectively, we
noted a relative reticulocytopenia with a maximum value of
120×109/l. She became hemodynamically unstable, and
vasopressor support and two more units of RBC were given
before she was intubated. She was extubated the following
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Figure 1: Time course of blood values obtained during and after the first episode. Reference ranges: Hb (11.7–15.3 g/dl); bilirubin (0.3–1.5
mg/dl); LDH (105–205U/l).
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hemolytic parameters were markedly reduced by day +9, and
she was discharged on day +13 with subsequent visits as an
outpatient. All bacterial cultures from this admission were
negative. Notably, during this first episode, DHTR was never
suspected.
2.2. Episode 2. Due to avascular necrosis of her right hip, the
patient underwent an arthroplasty in September 2018. On day
−3 prior to surgery, she received a planned transfusion with
three cross-matched units of RBC, raising her Hb to 11.0 g/dl.
Her pre-transfusion screening revealed no new alloantibodies.
After an uncomplicated orthopedic procedure on day 0, she
was transferred to our department. On day +3, she developed
skeletal pain but no symptoms related to the newly operated
hip. On suspicion of VOC, treatment was initiated with fluids,
analgesics, and antibiotics. As illustrated in Figure 2, her Hb
fell gradually towards her baseline level without any obvious
signs of bleeding or accelerated hemolysis during days 0 to +3.
However, on day +5, she developed rapid and marked he-
molysis with hemoglobinuria, Hb fell to 5.3 g/dl, and LDH
rose to above 1,000U/l. As noted in the first episode, there was
a lack of adequate reticulocyte response with values falling
from 413 to 177×109/l. We suspected DHTR, and further
transfusions were avoided. Intravenous immunoglobulin
therapy (30 g daily) was initiated for 4 days. On day +6, Hb
plummeted to 3.5 g/dl, and LDH and total bilirubin peaked at
1470U/l and 5.3mg/dl, respectively, and intravenous meth-
ylprednisolone (500 mg per day for 5 days) was administered.
Screening for new alloantibodies and a direct antiglobulin test
were both negative. Her HbA-fraction declined from 33.5% at
day 0 to 12.3% on day +6. Using the nomogram proposed by
Mekontso Dessap et al. [8], the likelihood of DHTR was
considered as high. Because of the critically low Hb, she
received one cross-matched unit of RBC on day +6. Ritux-
imab (an anti-CD20 antibody, 1000 mg i.v.) was given to-
gether with the transfusion. Two single doses of eculizumab
(an anti-complement factor 5 antibody, 900 mg i.v.) were
administered on days +6 and +12, whereas the erythropoietin
analogue darbepoietin (200 mg s.c.) was given every second
day from day +6 for a week. Over the next days, hemolysis
declined, and her Hb stabilized. On day +4, complement
factor C1q was 170 (reference 70–150) mg/l, increasing to
357mg/l on day +6, whereas after the administration of
eculizumab, markers of the classical, the lectin, and the al-
ternative pathways for complement activation were all re-
duced towards undetectable levels. Despite signs of significant
intravascular hemolysis, no serious organ dysfunction was
recorded. She was discharged on day +15. On follow-up, she
received pneumococcal and meningococcal vaccines. She had
a full recovery and was thereafter not admitted for VOC,
infections or transfusions.
2.3. Episode 3. Due to progressive avascular necrosis of the
contralateral hip, an arthroplasty was performed in March
2019. Screening for new alloantibodies and a direct anti-
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Figure 2: Time course of blood values obtained during and after the second episode. Reference range: reticulocytes (20–100×109/l).
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to optimize erythropoiesis, she received darbepoietin for two
months as well as hydroxyurea, but no prophylactic
transfusions. She maintained a preoperative Hb of about 8
g/dl, and she was also given one prophylactic dose of rit-
uximab (1000 mg i.v.) 2.5 weeks before surgery. Both the
surgery and the postoperative stay in hospital were un-
eventful and with no signs of hemolysis (Figure 3). She was
discharged one week later. Regular follow-up visits at the
outpatient clinic until December 2019 revealed no
complications.
3. Discussion
We here present a SCD patient who received preoperative
blood transfusions during two consecutive hospital ad-
missions which were most likely complicated by DHTR.
Although DHTR was not suspected during the first ad-
mission, we were alert to this complication during the
second admission. Hence, we were able to provide her with
adequate prophylactic treatment and avoided DHTR during
her third admission.
Retrospectively, we believe the symptoms she presented
during her postoperative hospital admission in 2017 rep-
resented the start of DHTR. A main challenge in identifying
DHTR in SCD patients is that the symptoms often mimic
VOC. In a large French observational study of about 3,000
SCD patients, the most common presenting symptoms and
signs were hemoglobinuria (94%), pain (89%), fever (64%),
and severe anemia (44%) [7]. Suppression of erythropoiesis
reflected in reticulocytopenia (<150×109/l) was observed in
40% of the patients. Progression to acute chest syndrome or
even multi-organ failure was not uncommon in the most
severe cases with an overall mortality of 6% [4]. Since
transfusions are sometimes indicated in VOC, such treat-
ment may further exacerbate hemolysis if DHTR is present
[4–6].
Hyperhemolysis refers to the destruction of allogenic
and autologous erythrocytes, potentially leading to severe
and fatal hemolysis [6,7]. In line with this, our patient had a
steep decline in Hb and spiking LDH on days +5 and +6
during the first and second episode, respectively. Alloanti-
body and direct antiglobulin screenings are imperative since
it can aid in early identification of “missed” or evanescent
antibodies. *is is important also because patients may be
treated at different institutions over the course of a lifetime,
and without universal medical records, they may receive
transfusions of blood with antibodies “lost to follow-up”.
Moreover, follow-up screenings at regular intervals fol-
lowing a diagnosed DHTR will increase the likelihood of
detecting new alloantibodies [9].
No new alloantibodies were detected in the acute setting
during the second episode, and a direct antiglobulin test was
negative. However, no repeated screenings were done be-
tween the first two episodes or after the second episode.
Neither did we perform extended antibody screening for
low-frequency antigens. Notably, hyperhemolysis may occur
without newly formed alloantibodies and has been described
in up to 1/3 of SCD patients [5, 8]. *e pathophysiology of
antibody negative DHTR is not fully understood, but may
involve macrophage activation and/or heme involvement
leading to endothelial damage and subsequent activation of
the alternative complement pathway [10, 11].
*ere is little evidence-based data for the therapeutic
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Figure 3: Time course of blood values obtained during and after the third episode. Reference range: haptoglobin (0.4–2.1 g/dl).
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treatment modalities are mainly based on expert recom-
mendations [12]. Immunoglobulins or high-dose steroids
are the recommended first-line therapy. Our patient re-
ceived both agents as her hemolysis spiked, however, Hb still
plummeted to 3.4 g/dl. We therefore chose to give a single
transfusion at this critical anemia. We gave rituximab prior
to transfusion to prevent new alloantibodies [13]. Relative
reticulocytopenia secondary to suppressed erythropoiesis is
a feature of DHTR, and it was observed in our patient during
both episodes 1 and 2. To stimulate endogenous blood
production, we administered an erythropoietin analogue.
Eculizumab has been used in the management of patients
with severe DHTR and severe hemolysis [14]. Our patient
had elevated C1q indicating increased complement activa-
tion and thus received eculizumab along with rituximab. We
do not know which agent contributed most to the resolution
of the hemolysis, so we can only speculate that eculizumab
was the most effective drug since it is known to result in
rapid reduction of hemolysis [15].
DHTR is a rare life-threatening complication to trans-
fusions in SCD patients. Our patient illustrates the dilemma
that DHTR can be misdiagnosed as VOC, a complication of
SCD that is much more common than DHTR. Hence, a
DHTR diagnosis should always be considered in the pres-
ence of an unexplained increase in hemolysis following a
recent transfusion, and further transfusions should be
avoided unless life-threatening anemia is present.
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